Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology (ORHEO)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The main aim of this study is to observe correction of the hemoglobin level in the patients under chemotherapy, treated with epoetin alfa biosimilar and presenting with a solid tumor or a lymphoma or a myeloma.
This is a non-interventional, descriptive, national, multi-site, longitudinal and prospective observational study with adults patients who are suffering from cancer or malignant blood disease and whose chemotherapy treatment has induced symptomatic anemia and being treated with biosimilar of epoetin to correct haemoglobin levels.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients suffer from solid tumours, malignant lymphomas or multiple myeloma and have developed symptomatic anaemia due to their chemotherapy.
Patients of more than 18 years of age
Patients presenting with anemia following chemotherapy
Patients suffer from solid tumours, malignant hemopathies, lymphomas or myelomas and presenting with anemia following chemotherapy
-- The patients may be included regardless of their chemotherapy cycle (from the first cycle until the last cycle)
Patients eligible for epoetin alfa biosimilar treatment
Patients are not receiving chemotherapy
Patients already included in an epoetin zeta trial
Patients presenting with a contraindication to epoetin zeta
Patients presenting with hypersensitivity to the active principle or any of the excipients
Patient with erythroblastopenia or acquired pure red cell aplasia (APRCA)
Patient with uncontrollable arterial hypertension
Patients who cannot receive adequate prophylaxis by antithrombotic agents